Giuseppe Rosiello1,2, Angela Pecoraro3,4, Carlotta Palumbo3,5, Sophie Knipper3,6, Stefano Luzzago3,7, Marina Deuker8, Zhe Tian3, Giorgio Gandaglia9, Nicola Fossati9, Francesco Montorsi9, Shahrokh F Shariat10,11, Fred Saad3, Alberto Briganti9, Pierre I Karakiewicz3. 1. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. giusepperosiello@hotmail.it. 2. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina, 52, 20132, Milan, Italy. giusepperosiello@hotmail.it. 3. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. 4. Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy. 5. Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy. 6. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 7. Department of Urology, European Institute of Oncology, Milan, Italy. 8. Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. 9. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina, 52, 20132, Milan, Italy. 10. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 11. Institute of Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Abstract
PURPOSE: To test the effect of perioperative chemotherapy (CHT) on overall mortality (OM) and cancer-specific mortality (CSM) in patients with locally advanced or metastatic squamous cell carcinoma of the urinary bladder (SCC UB). METHODS: Within the Surveillance, Epidemiology and End Results database (1988-2016), we identified 1,018 SCC UB patients (664 T3-4aN0M0, 197 TanyN1-3M0 and 156 T4bN0-3 or M1), who underwent radical cystectomy with or without perioperative chemotherapy administration. Inverse probability of treatment-weighting (IPTW), Kaplan-Meier plots and Cox-regression models (CRMs) were used. RESULTS: CHT was administrated in 116 (17.5%) T3-4aN0M0, 77 (39.1%) TanyN1-3M0 and 47 (30.1%) T4bN0-3 or M1 patients. IPTW-adjusted 2-year cancer-specific survival (CSS) was 66.5 vs. 71.5% (p = 0.19), 60.9 vs. 29.5% (p < 0.001) and IPTW-adjusted 1-year CSS was 46.2 vs. 31.1% (p = 0.03) for CHT vs. no CHT administration in T3-4aN0M0, TanyN1-3M0 and T4bN0-3 or M1, respectively. In multivariable IPTW-adjusted CRMs, chemotherapy was an independent predictor of lower CSM in TanyN1-3M0 (HR 0.44) and in T4bN0-3 or M1 (HR 0.60), but not in T3-4aN0M0 (p = 0.6) patients. Virtually the same results were obtained on OM, as well as without IPTW-adjustment and after stratification according to age and gender. CONCLUSIONS: The use of perioperative CHT in patients with SCC UB confers survival benefit in the presence of T4b disease, lymph node or distant metastases. Conversely, patients with locally advanced disease but negative lymph node invasion do not benefit from its use. Pending higher quality data from prospective trials, these data should encourage the use of perioperative CHT in those high-risk patient groups.
PURPOSE: To test the effect of perioperative chemotherapy (CHT) on overall mortality (OM) and cancer-specific mortality (CSM) in patients with locally advanced or metastatic squamous cell carcinoma of the urinary bladder (SCC UB). METHODS: Within the Surveillance, Epidemiology and End Results database (1988-2016), we identified 1,018 SCC UB patients (664 T3-4aN0M0, 197 TanyN1-3M0 and 156 T4bN0-3 or M1), who underwent radical cystectomy with or without perioperative chemotherapy administration. Inverse probability of treatment-weighting (IPTW), Kaplan-Meier plots and Cox-regression models (CRMs) were used. RESULTS: CHT was administrated in 116 (17.5%) T3-4aN0M0, 77 (39.1%) TanyN1-3M0 and 47 (30.1%) T4bN0-3 or M1 patients. IPTW-adjusted 2-year cancer-specific survival (CSS) was 66.5 vs. 71.5% (p = 0.19), 60.9 vs. 29.5% (p < 0.001) and IPTW-adjusted 1-year CSS was 46.2 vs. 31.1% (p = 0.03) for CHT vs. no CHT administration in T3-4aN0M0, TanyN1-3M0 and T4bN0-3 or M1, respectively. In multivariable IPTW-adjusted CRMs, chemotherapy was an independent predictor of lower CSM in TanyN1-3M0 (HR 0.44) and in T4bN0-3 or M1 (HR 0.60), but not in T3-4aN0M0 (p = 0.6) patients. Virtually the same results were obtained on OM, as well as without IPTW-adjustment and after stratification according to age and gender. CONCLUSIONS: The use of perioperative CHT in patients with SCC UB confers survival benefit in the presence of T4b disease, lymph node or distant metastases. Conversely, patients with locally advanced disease but negative lymph node invasion do not benefit from its use. Pending higher quality data from prospective trials, these data should encourage the use of perioperative CHT in those high-risk patient groups.
Authors: Shaheen Alanee; Isabel Alvarado-Cabrero; Paari Murugan; Rajeev Kumar; Kenneth G Nepple; Gladell P Paner; Manish I Patel; Maria Rosaria Raspollini; Antonio Lopez-Beltran; Badrinath R Konety Journal: World J Urol Date: 2018-08-01 Impact factor: 4.226
Authors: Nawar Hanna; Quoc-Dien Trinh; Thomas Seisen; Malte W Vetterlein; Jesse Sammon; Mark A Preston; Stuart R Lipsitz; Joaquim Bellmunt; Mani Menon; Toni K Choueiri; Firas Abdollah Journal: Eur Urol Oncol Date: 2018-05-15
Authors: Behfar Ehdaie; Alexandra Maschino; Shahrokh F Shariat; Jorge Rioja; Robert J Hamilton; William T Lowrance; Stephen A Poon; Hikmat A Al-Ahmadie; Harry W Herr Journal: J Urol Date: 2011-11-16 Impact factor: 7.450
Authors: Craig G Rogers; Ganesh S Palapattu; Shahrokh F Shariat; Pierre I Karakiewicz; Patrick J Bastian; Yair Lotan; Amit Gupta; Amnon Vazina; Amiel Gilad; Arthur I Sagalowsky; Seth P Lerner; Mark P Schoenberg Journal: J Urol Date: 2006-06 Impact factor: 7.450
Authors: Luca Boeri; Matteo Soligo; Igor Frank; Stephen A Boorjian; R Houston Thompson; Matthew Tollefson; Fernando J Quevedo; John C Cheville; R Jeffrey Karnes Journal: Eur Urol Oncol Date: 2018-09-28
Authors: J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal Journal: Eur Urol Date: 2016-06-30 Impact factor: 20.096
Authors: Fern Anari; John O'Neill; Woonyoung Choi; David Y T Chen; Mohammed Haseebuddin; Alexander Kutikov; Essel Dulaimi; R Katherine Alpaugh; Karthik Devarajan; Richard E Greenberg; Marijo Bilusic; Yu-Ning Wong; Rosalia Viterbo; Jean H Hoffman-Censits; Costas D Lallas; Edouard J Trabulsi; Marc Smaldone; Daniel M Geynisman; Matthew Zibelman; Jianqing Lin; W Kevin Kelly; Robert Uzzo; David McConkey; Elizabeth R Plimack Journal: Eur Urol Oncol Date: 2018-06-06
Authors: Chiara Lonati; Luca Afferi; Andrea Mari; Andrea Minervini; Wojciech Krajewski; Marco Borghesi; Gerald B Schulz; Michael Rink; Francesco Montorsi; Alberto Briganti; Renzo Colombo; Alberto Martini; Andrea Necchi; Roberto Contieri; Rodolfo Hurle; Paolo Umari; Stefania Zamboni; Claudio Simeone; Francesco Soria; Giancarlo Marra; Paolo Gontero; Jeremy Yuen-Chun Teoh; Tobias Klatte; Anne-Sophie Bajeot; Mathieu Roumiguié; Morgan Rouprêt; Alexandra Masson-Lecomte; Ekaterina Laukhtina; Anne Sophie Valiquette; M Carmen Mir; Alessandro Antonelli; Sarah M H Einerhand; Kees Hendricksen; Roberto Carando; Christian D Fankhauser; Philipp Baumeister; Agostino Mattei; Shahrokh F Shariat; Marco Moschini Journal: World J Urol Date: 2022-02-26 Impact factor: 4.226
Authors: Giuseppe Rosiello; Carlotta Palumbo; Marina Deuker; Lara Franziska Stolzenbach; Thomas Martin; Zhe Tian; Andrea Gallina; Francesco Montorsi; Peter Black; Wassim Kassouf; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Cent European J Urol Date: 2020-10-31